McMasters David 4/A

4/A · ANGIOTECH PHARMACEUTICALS INC · Filed May 17, 2011

Form 4/AAmended

Period: 2011-05-12

Sr VP, Legal & General Counsel

Transactions

Other
Stock Option w/Tandem SAR
2011-05-12−135,000→ 600,000 total
Exercise: $1.05From: 2010-04-01Exp: 2015-03-07→ Common Stock (135,000 underlying)
Other
Common Stock
2011-05-12−800→ 0 total
Other
Common Stock
2011-05-12−2,000→ 800 total(indirect: By Spouse)
Other
Stock Option w/Tandem SAR
2011-05-12−200,000→ 400,000 total
Exercise: $0.27From: 2009-04-01Exp: 2014-03-09→ Common Stock (200,000 underlying)
Other
Stock Option w/Tandem SAR
2011-05-12−200,000→ 200,000 total
Exercise: $0.16From: 2009-01-01Exp: 2013-12-07→ Common Stock (200,000 underlying)
Other
Stock Option w/Tandem SAR
2011-05-12−200,000→ 0 total
Exercise: $0.16From: 2009-01-01Exp: 2013-12-07→ Common Stock (200,000 underlying)
Other
Awards (Options w/Tandem SAR)
2011-05-12−50,000→ 175,000 total
Exercise: $13.47From: 2002-12-01Exp: 2012-12-17→ Common Stock (50,000 underlying)
Other
Awards (Options w/Tandem SAR)
2011-05-12−175,000→ 0 total
Exercise: $7.65From: 2007-03-01Exp: 2012-02-04→ Common Stock (175,000 underlying)

Footnotes (1)

[F1]Effective on May 12, 2011, all of the Company's existing common shares and options to acquire common shares were canceled without any payment or consideration therefor, in connection with the implementation of a plan of compromise or arrangement under the Companies' Creditors Arrangement Act (Canada).

Documents

1 file